The success of several FDA-approved platinum anticancer drugs has stimulated increasing
interest in the development of new metallodrugs.[1] Ruthenium (Ru) complexes are potential …

Traditional photodynamic phototherapy is not efficient for anticancer treatment because solid
tumors have a hypoxic microenvironment. The development of photoactivated …

As an effective and noninvasive treatment of various diseases, photodynamic therapy (PTD)
relies on the combination of light, a photosensitizer, and oxygen to generate cytotoxic …

The use of visible light to produce highly selective and potent drugs through photodynamic
therapy (PDT) holds much potential in the treatment of cancer. PDT agents can be designed …

Platinum (Pt)-based anticancer drugs such as cisplatin have been used to treat various
cancers. However, they have some limitations including poor selectivity and toxicity towards …

The synergistic combination of chemotherapy and photodynamic therapy has attracted
considerable attention for its enhanced antitumoral effects; however, it remains challenging …

The use of photodynamic therapy (PDT) against cancer has received increasing attention
over recent years. However, the application of the currently approved photosensitizers (PSs) …

In this study, we reported a tamoxifen modified Ru (II) polypyridyl complex (Ru-tmxf) as an
estrogen receptor (ER) targeted photosensitizer. Ru-tmxf displays enhanced cellular uptake …

Photodynamic therapy (PDT) represents a promising approach for cancer treatment.
However, the oxygen dependency of PDT to generate reactive oxygen species (ROS) …

Platinum-resistant cancer cells are sensitive to changes in the levels of reactive oxidative
species (ROS). Herein, we design a biotin-modified Ru (II) complex as a photosensitizer …